$GRI
GRI Bio, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · La Jolla, CA
GRI chart
What traders are saying about $GRI
Latest postsGRI Bio, Inc. news
- What Pushed GRI Bio (NASDAQ:GRI) Down 16.48% to About USD 0.79 Intraday?
kalkine.ca ·
- Primary Sclerosing Cholangitis Pipeline Update 2026: Clinical Development Status, Collaborations, and Key Companies to Watch | Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharma
StreetInsider ·
- GRI Bio, Inc. Estimates – NASDAQ:GRI
TradingView ·
- GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
Yahoo Finance ·
- GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?
Yahoo Finance ·
- GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
Yahoo Finance ·
- GRI Bio Featured in "Why Now" On-Demand Video Webcast
Yahoo Finance ·
- GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
Yahoo Finance ·
- GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Yahoo Finance ·
- GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
Yahoo Finance ·
- GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Yahoo Finance ·
- Grainger H1 Earnings Call Highlights
marketbeat.com ·
GRI Bio, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$12.0M | -$8.2M | -$13.0M | -$3.2M |
| Diluted EPS | $-121.80 | $-1545.55 | $-5018.09 | $-24.95 |
| Total assets (year end) | $8.7M | $5.7M | $3.0M | $383,000 |
| Cash and equivalents (year end) | $8.2M | $5.0M | $1.8M | $9,000 |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About GRI Bio, Inc.
- Ticker
- GRI (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- La Jolla, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1824293
- Former names
- Vallon Pharmaceuticals, Inc.
Frequently asked questions
What exchange is GRI Bio, Inc. listed on?
GRI Bio, Inc. trades on the Nasdaq under the ticker symbol GRI.
What industry is GRI Bio, Inc. in?
GRI Bio, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is GRI Bio, Inc. headquartered?
GRI Bio, Inc.'s business address on file with the SEC is in La Jolla, CA.
When does GRI Bio, Inc.'s fiscal year end?
GRI Bio, Inc.'s fiscal year ends on December 31.
How much revenue did GRI Bio, Inc. report?
GRI Bio, Inc. reported $0 in revenue for calendar year 2021, according to its SEC filings.